12 results about "Cystatin S" patented technology

The invention discloses application of an RNF130 activator in preparation of a medicine for preventing and / or treating acute kidney injury, and belongs to the technical field of biological medicine. The invention provides an application of an RNF130 activator in preparation of a medicine for preventing or treating renal ischemia-reperfusion injury, the RNF130 activator can improve the renal function of a mouse suffering from renal ischemia-reperfusion injury, improve the levels of serum creatinine, urea nitrogen and cystatin C, reduce the levels of kidney injury markers KIM-1 and LCN2, reduce renal tubule injury, improve the renal function of the mouse suffering from renal ischemia-reperfusion injury, improve the renal function of the mouse suffering from renal ischemia-reperfusion injury and improve the renal function of the mouse suffering from renal ischemia-reperfusion injury and the renal function of the mouse suffering from renal ischemia-reperfusion injury. Therefore, the compound plays a role in preventing and treating the kidney ischemia reperfusion injury, and a new target is provided for preparing the medicine for preventing and treating the acute kidney injury.

The invention belongs to the technical field of microorganisms, and particularly relates to bifidobacterium animalis subsp. Lactis, a product and application of the bifidobacterium animalis subsp. Lactis in liver protection. The preservation number of the bifidobacterium animalis subsp. Lactis BB-35 provided by the invention is CGMCC (China General Microbiological Culture Collection Center) No.27836, and the preservation number of the bifidobacterium animalis subsp. Lactis BB-35 provided by the invention is CGMCC No.27836. The strain can be used for reducing the expression condition of a senescence-related marker p21 in liver cells of mice, and reducing the level of senescence-related secretory phenotype factors, the level of cystatin C and liver function-related biochemical indexes, so that the liver senescence condition of the mice is improved, and the influence on other organs is reduced; in addition, the strain can also improve oxidative stress index malonaldehyde and superoxide dismutase content, reduce inflammatory factor TNF-alpha and IL-6 levels, and provide technical support for preparation of products for preventing, relieving and / or treating liver aging and liver injury.

The present invention belongs to the field of microbial technology, and particularly relates to a strain of Bifidobacterium animalis subsp. lactis, a product and its application in protecting the liver. The Bifidobacterium animalis subsp. lactis ( Bifidobacterium animalis subsp. lactis ) BB-35 provided by the present invention has a preservation number of CGMCC No. 27836. This strain can be used to reduce the expression of the senescence-related marker p21 in mouse hepatocytes, reduce the levels of senescence-related secretory phenotype factors, cystatin C levels and liver function-related biochemical indicators, thereby improving the liver senescence condition of mice and reducing the impact on other organs. In addition, this strain can also improve the oxidative stress indicators malondialdehyde and superoxide dismutase contents, and reduce the levels of inflammatory factors TNF-α and IL-6, providing technical support for the preparation of products for preventing, alleviating and / or treating liver senescence and liver injury.

The application discloses an application of an RNF130 activator in preparation of a medicine for preventing and / or treating acute kidney injury, and belongs to the technical field of biological medicines.The application provides an application of the RNF130 activator in preparation of a medicine for preventing or treating kidney ischemia-reperfusion injury, and the RNF130 activator can improve kidney function of a mouse with kidney ischemia-reperfusion injury, improve levels of blood creatinine, urea nitrogen and cystatin C, reduce levels of kidney injury markers KIM-1 and LCN2, and reduce tubular injury, thereby playing a preventive and therapeutic role on kidney ischemia-reperfusion injury, and providing a new target for preparation of a medicine for preventing and treating acute kidney injury.

The invention belongs to the technical field of medicines, and particularly relates to combined application of a pollen pini aqueous extract and fucoidin in preparation of a medicine for preventing and / or treating renal injury. According to the invention, cell experiment results show that the combination of the pollen pini aqueous extract and the fucoidin has an obvious synergistic effect, the relative activity of HK-2 cells can be obviously improved, the cell apoptosis and ROS level caused by adriamycin can be reduced, and the energy metabolism function of the HK-2 cells can be obviously improved; animal experiment results show that the combination of the pollen pini aqueous extract and the fucoidin can significantly reduce the levels of serum creatinine (Crea), urea nitrogen (Urea) and cystatin C (Cys-C), improve the pathological injury of kidney tissues, relieve the fibrosis process, and provide a theoretical basis and an innovative direction for developing a new strategy for intervention of kidney injury.

The utility model discloses an experiment table for serum cystatin experiment in the technical field of reagent determination, which comprises a kit, a plurality of electric telescopic rods are arranged in the kit, a lifting plate is arranged at the power ends of the electric telescopic rods, the lifting plate is fixedly connected with the power ends of the electric telescopic rods, a plurality of limiting blocks are arranged at the top of the lifting plate, and the limiting blocks are fixedly connected with the lifting plate. The limiting block is fixedly connected with the lifting plate, a plurality of elastic belts are arranged at the top of the lifting plate, the elastic belts are fixedly connected with the lifting plate, a cushioning sponge is arranged at the top of the lifting plate, the cushioning sponge is fixedly connected with the lifting plate, reagent tubes are arranged in the elastic belts, and a sealing plug is arranged at one end of each reagent tube. By arranging the kit, the electric telescopic rod, the lifting plate, a limiting block, an elastic belt, a cushioning sponge, a reagent tube, a sealing plug, a limiting hole and a through hole, the test bed for the serum cystatin experiment achieves the function of transporting and protecting an experimental reagent, and the safety of reagent protection is improved.

To develop a new, simple method that can be an index for a kidney function decline risk in diabetes, particularly, type 2 diabetes.SOLUTION: Provided is a method for evaluating a kidney function decline risk in a subject having diabetes, the method including: (A) a step of acquiring a body fluid sample obtained from the subject; and (B) a step of measuring the concentration of cystatin A present in the body fluid sample.SELECTED DRAWING: None

The present invention relates to the technical field of pathogen and disease marker detection, and specifically to an ultra-small high-entropy alloy for lateral flow immunochromatography, and its preparation method and application. The preparation method of the high-entropy alloy comprises the following steps: preparing a precursor solution; preparing the high-entropy alloy by a low-temperature reduction-diffusion strategy. The high-entropy alloy prepared by the method of the present invention has excellent catalytic performance and ultra-high peroxidase simulation activity. When applied to lateral flow immunochromatography, it can quickly and accurately detect Staphylococcus aureus, and has the characteristics of high sensitivity and strong specificity. At the same time, the present invention successfully extends the application of the high-entropy alloy to the detection of kidney injury marker cystatin C by modifying the recognition element. The high-entropy alloy for lateral flow immunochromatography provided by the present invention has huge market promotion prospects in the field of pathogen and disease marker detection.

This invention discloses an electrochemical sensor for detecting Cys C, its preparation method, and a method for detecting Cys C. The electrochemical sensor for detecting Cys C includes a working electrode, a reference electrode, and a counter electrode. The working electrode comprises an electrode substrate and nanomaterials and a Cys C aptamer sequentially modified on the electrode substrate. The nanomaterials are MoS2 nanomaterials or gold nanomaterials. The 5′ end of the Cys C aptamer is modified with an electroactive substance X, where X is ferrocene or methylene blue. The 3′ end of the Cys C aptamer is modified with a group Y, where Y is -(CH2). n -SH, where n is a natural number from 1 to 12. The electrochemical sensor of this invention can be used for in vivo quantitative detection of Cys C, and exhibits good performance in terms of cost-effectiveness, ease of operation, and the use of environmentally friendly materials. It is a potential electrochemical sensor for early diagnosis of CKD.

This invention provides reagents and methods for diagnosing renal disease. Differential levels of inosine metabolite, and proteins: apolipoprotein C-I, apolipoprotein C-II, fibrinogen alpha chain, or fibrinogen A-alpha chain, kininogen, Inter-Alpha Inhibitor H4 (ITIH4), keratin Type I cytoskeletol 10 cystatin A, cystatin B and other polypeptides and fragments thereof provide biomarkers of renal disease and are described herein.

The invention relates to a marker, a primer pair and a kit for evaluating the hematopoietic injury level and application of the marker, the primer pair and the kit, and belongs to the technical field of biomedicine. The marker for evaluating the hematopoietic injury level is cystatin A; the nucleotide sequence of the cystatin A is as shown in SEQ ID NO. 1. The cystatin A can be used as a marker for evaluating hematopoietic injury caused by long-term contact with toxic substances such as benzene, and has good sensitivity, specificity and accuracy.

Biomarkers associated with being at risk of chemotherapy-induced cardiotoxicity are described. The identified biomarkers include biglycan (BGN), carbonic anhydrase 6 (CA6), CD109, thrombospondin-4 (TSP4), cadherin-5 (CDH5) and cystatin-F (CST7). Methods of identifying subjects diagnosed with cancer as being at risk for chemotherapy-induced cardiotoxicity, such as toxicity induced by an anthracycline, by measuring the level of one or more of the disclosed biomarkers, are also described. Kits for detecting the biomarkers associated with chemotherapy-induced cardiotoxicity are also described.